← Back to Search

Social Function Training for Psychosis

N/A
Waitlist Available
Led By Joanna M. Fiszdon, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Veteran with diagnosis of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, delusional disorder, psychosis NOS, etc);
Be older than 18 years old
Must not have
diagnosis of medical or neurological illness known to impair brain function including dementia, presence of seizures, history of head trauma with loss of consciousness > 1hr, or clear cognitive sequelae from other illness or injury
severe, uncorrected auditory/visual impairment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-training, mid-training (1 month), post-training (2 months), follow-up (4 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing which of two different types of training courses is more effective in improving social function for people with psychotic spectrum disorders.

Who is the study for?
This trial is for Veterans fluent in English who have been psychiatrically stable for at least 30 days and diagnosed with a psychotic disorder. They must be able to consent legally to participate. Those with developmental disabilities, current substance use disorders, severe sensory impairments, or other medical conditions affecting brain function cannot join.
What is being tested?
The study compares two different 2-month training programs designed to improve social functioning and quality of life in people with psychotic spectrum disorders. The effectiveness of USS versus MovingForward training courses will be evaluated.
What are the potential side effects?
Since the interventions are training programs rather than medications, traditional side effects are not applicable. However, participants may experience varying levels of stress or emotional discomfort during the course of the trainings.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a veteran diagnosed with a psychotic disorder.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not been diagnosed with any brain impairing conditions like dementia or severe head trauma.
Select...
I have severe hearing or vision problems that can't be corrected.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-training, mid-training (1 month), post-training (2 months), follow-up (4 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-training, mid-training (1 month), post-training (2 months), follow-up (4 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Social Functioning Scale (SFS) Change
Secondary study objectives
Social Skills Performance Assessment (SSPA) Change

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: USSExperimental Treatment1 Intervention
social cognitive training
Group II: MovingForwardActive Control1 Intervention
problem solving training

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,664 Previous Clinical Trials
3,765,707 Total Patients Enrolled
7 Trials studying Psychosis
1,639 Patients Enrolled for Psychosis
Joanna M. Fiszdon, PhDPrincipal InvestigatorVA Connecticut Healthcare System West Haven Campus, West Haven, CT
2 Previous Clinical Trials
254 Total Patients Enrolled
1 Trials studying Psychosis
114 Patients Enrolled for Psychosis

Media Library

MovingForward Clinical Trial Eligibility Overview. Trial Name: NCT04557124 — N/A
Psychosis Research Study Groups: USS, MovingForward
Psychosis Clinical Trial 2023: MovingForward Highlights & Side Effects. Trial Name: NCT04557124 — N/A
MovingForward 2023 Treatment Timeline for Medical Study. Trial Name: NCT04557124 — N/A
~22 spots leftby Nov 2025